|
|
|
|
| LEADER |
03940nma a2201237 u 4500 |
| 001 |
EB002048224 |
| 003 |
EBX01000000000000001191890 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
220822 ||| eng |
| 020 |
|
|
|a 9783036502700
|
| 020 |
|
|
|a 9783036502717
|
| 020 |
|
|
|a books978-3-0365-0271-7
|
| 100 |
1 |
|
|a López, José I.
|
| 245 |
0 |
0 |
|a Urological Cancer 2020
|h Elektronische Ressource
|
| 260 |
|
|
|a Basel, Switzerland
|b MDPI - Multidisciplinary Digital Publishing Institute
|c 2021
|
| 300 |
|
|
|a 1 electronic resource (334 p.)
|
| 653 |
|
|
|a radiotherapy
|
| 653 |
|
|
|a machine learning
|
| 653 |
|
|
|a transcriptome
|
| 653 |
|
|
|a metastatic spread
|
| 653 |
|
|
|a oncogenes
|
| 653 |
|
|
|a biphasic imaging
|
| 653 |
|
|
|a optical mapping
|
| 653 |
|
|
|a MR-guided
|
| 653 |
|
|
|a angiogenesis
|
| 653 |
|
|
|a prostatic neoplasms/epidemiology
|
| 653 |
|
|
|a stereotactic ablative radiation therapy (SABR)
|
| 653 |
|
|
|a n/a
|
| 653 |
|
|
|a tumorigenesis
|
| 653 |
|
|
|a urothelial carcinoma
|
| 653 |
|
|
|a cell proliferation
|
| 653 |
|
|
|a fatty acids
|
| 653 |
|
|
|a diagnosis
|
| 653 |
|
|
|a patient-derived xenografts
|
| 653 |
|
|
|a deep learning
|
| 653 |
|
|
|a antiangiogenic therapy
|
| 653 |
|
|
|a PD1
|
| 653 |
|
|
|a androgen response
|
| 653 |
|
|
|a stage T1 NMIBC
|
| 653 |
|
|
|a α1-adrenoceptor antagonists
|
| 653 |
|
|
|a stereotactic ablative radiotherapy
|
| 653 |
|
|
|a prostate mpMRI
|
| 653 |
|
|
|a CXCL9
|
| 653 |
|
|
|a ROS
|
| 653 |
|
|
|a stroma signature
|
| 653 |
|
|
|a differential diagnosis
|
| 653 |
|
|
|a whole genome sequencing
|
| 653 |
|
|
|a therapy
|
| 653 |
|
|
|a PD-L1
|
| 653 |
|
|
|a bladder cancer
|
| 653 |
|
|
|a renal tumors
|
| 653 |
|
|
|a renal cell cancer
|
| 653 |
|
|
|a RCC
|
| 653 |
|
|
|a MRgRT
|
| 653 |
|
|
|a lesion positivity rate
|
| 653 |
|
|
|a prostate cancer
|
| 653 |
|
|
|a CPT1A
|
| 653 |
|
|
|a microtubule
|
| 653 |
|
|
|a MAP1B
|
| 653 |
|
|
|a chelation therapy
|
| 653 |
|
|
|a Research & information: general / bicssc
|
| 653 |
|
|
|a [68Ga]Ga-PSMA PET/CT
|
| 653 |
|
|
|a delayed imaging
|
| 653 |
|
|
|a histopathology
|
| 653 |
|
|
|a macrophages
|
| 653 |
|
|
|a Biology, life sciences / bicssc
|
| 653 |
|
|
|a prognosis
|
| 653 |
|
|
|a KLF5
|
| 653 |
|
|
|a biomarker
|
| 653 |
|
|
|a online adaptive
|
| 653 |
|
|
|a serine
|
| 653 |
|
|
|a DONSON
|
| 653 |
|
|
|a androgen receptor
|
| 653 |
|
|
|a renal cell carcinoma
|
| 653 |
|
|
|a iron
|
| 653 |
|
|
|a tumor suppressor genes
|
| 653 |
|
|
|a artificial intelligence
|
| 653 |
|
|
|a transurethral resection
|
| 653 |
|
|
|a oxidative stress
|
| 653 |
|
|
|a prostatic neoplasms/mortality
|
| 653 |
|
|
|a angiogenic growth factors
|
| 653 |
|
|
|a prevention
|
| 653 |
|
|
|a dual-time point imaging
|
| 653 |
|
|
|a prostate carcinoma
|
| 653 |
|
|
|a en-bloc resection
|
| 653 |
|
|
|a SEER Program
|
| 653 |
|
|
|a precision medicine
|
| 653 |
|
|
|a vascularity
|
| 653 |
|
|
|a anoikis
|
| 653 |
|
|
|a immunohistochemistry
|
| 653 |
|
|
|a research model
|
| 653 |
|
|
|a neural network
|
| 653 |
|
|
|a Downstream Neighbor of SON
|
| 700 |
1 |
|
|a López, José I.
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b DOAB
|a Directory of Open Access Books
|
| 500 |
|
|
|a Creative Commons (cc), https://creativecommons.org/licenses/by/4.0/
|
| 028 |
5 |
0 |
|a 10.3390/books978-3-0365-0271-7
|
| 856 |
4 |
0 |
|u https://www.mdpi.com/books/pdfview/book/4203
|7 0
|x Verlag
|3 Volltext
|
| 856 |
4 |
2 |
|u https://directory.doabooks.org/handle/20.500.12854/76754
|z DOAB: description of the publication
|
| 082 |
0 |
|
|a 000
|
| 082 |
0 |
|
|a 610
|
| 082 |
0 |
|
|a 540
|
| 082 |
0 |
|
|a 700
|
| 520 |
|
|
|a This Urological Cancer 2020 collection contains a set of multidisciplinary contributions to the extraordinary heterogeneity of tumor mechanisms, diagnostic approaches, and therapies of the renal, urinary tract, and prostate cancers, with the intention of offering to interested readers a representative snapshot of the status of urological research.
|